Joint Programming Initiative on Antimicrobial Resistance

Developing, maintaining and updating the strategic research agenda


To develop, maintain and update a Strategic Research Agenda (SRA) which will provide a framework for future investment and research activity within the JPIAMR. In order to achieve this, WP3 will:

  • In close collaboration with the Scientific Advisory Board (SAB), consider the strengths and weaknesses of relevant research programmes and portfolios across the EU, both within individual participating countries as well as those funded under cross border activities.
  • Work with the SAB to identify the opportunities and gaps that might be addressed through the JPIAMR initiative, to highlight areas where current unnecessary duplication might be minimised, and to seek synergies with other European and international activities.
  • Advise on future capacity building and infrastructure requirements to support the area.

Description of work and role of partners

This WP will build on the development work already undertaken. All member states endorsed the Vision Paper
in April 2011. This outlines several overarching research questions to be answered in the next 15 years. WP3
will build on the Vision Paper and translate it into the SRA. In July 2011, 14 experts were elected by the MB to
become members of the SAB. Their input, as well as that from relevant stakeholders will be used to develop the SRA, on which the MB will have the final vote.

Task 3.1 Targeted mapping (M1 to M12) (Task leader: MRC; Contributors: INSERM)

Top-level research portfolio mapping data has already been collected on the majority of participating states.
That exercise collated data on major national and EU-wide programmes and initiatives, networks, centres
of excellence and programmatic funding. This will be extended to include MS which joined the JPI after the
initial exercise. To underpin the work of the SAB in developing the SRA, data will be analysed to provide an
objective view of the level and strength of research activity across Europe, which will help identify both gaps and opportunities.

To build on this, the SAB, with input from the SHAB and MB, will identify where further in depth mapping is
required to support the SRA. The mapping will identify on-going relevant EU research activity in the academic
sector, but will also seek to engage industry, service providers and national surveillance programmes. This will
provide information on the key investments across the EU and will provide context for the development of the
SRA and future JPI activities. Data will be collated in a consistent and accessible format, which will be made
publicly accessible.

Task 3.2 Foresight activities (M1 to M12) (Task leader: ZonMw; Contributors: JÜLICH)

Methods for foresight and horizon scanning will be developed. An initial foresight exercise will be undertaken and methods agreed upon for on-going foresight activities within the CSA period and beyond. The methodological approaches may evolve and be re-defined throughout the process, depending on the availability of appropriate information. The role of foresight is to identify and characterise the scientific challenges with regard to antimicrobial resistance and the ways in which they might impact on society. Therefore, the exercise will be problem-oriented and examine scenarios focused on identification of scientific challenges which society faces in addressing the issue of increasing antimicrobial resistance. The scenarios will reveal various challenges. A workshop with experts on foresight activities and relevant stakeholders will be organised to discuss and develop specific methodological approaches for JPIAMR. The JPI advisory bodies will be actively involved in developing and evaluating results and outputs in each stage of this process. This approach will ensure that the outputs of this process will be reliable and credible and will maximize the impact of the outcomes and recommendations.

Task 3.3 Scientific priorities of the SRA by SAB (M1 to M12)
(Task leader: ZonMw; Contributors: MRC, INSERM)

The WP will utilise the SAB to develop the SRA and to identify European-wide research priorities. The SAB will
consider the whole spectrum of research activity, spanning basic discovery science to strategically directed
research. In the Vision Paper three areas of interest were described. The SAB has already started to translate this into the SRA; however, mapping and foresight will also provide valuable input (tasks 3.1 and 3.2). The composition of the SAB has been chosen to broadly represent the research disciplines prioritised in the Vision Paper, although in depth analysis might require more specialised workshops involving additional experts on an ad hoc basis. The SAB will develop a concept for a SRA, on which input will be given via a web-based consultation. In addition, national consultations will be held using the National Expert Panels and stakeholders will be consulted as outlined in WP5. This will enlarge the area of expertise and create a solid basis for the SRA.

A prioritisation exercise will then be undertaken through a series of workshops with different research themes.
These will involve leading experts and stakeholders to identify the issues that will support the development of
the SRA. The outputs of the workshops will be publicly available reports summarising the specific research
opportunities and gaps identified. A final workshop will then integrate the outputs of the specific activities, leading to overall recommendations to be considered. This will be used as the basis for a final SAB report identifying a coherent set of opportunities, objectives and priorities which will be considered by the MB under task 3.4. WP4 will work in close association with this activity to ensure that emerging ideas and concepts are fed into the scoping stages of the implementation activity.

Task 3.4 Strategic prioritisation and delivery of SRA (M1 to M36)
(Task leader: ZonMw; Contributors: MRC, JÜLICH, INSERM)

The WP will finalise the SRA through the Management Board, based upon the recommendations and advice
from the SAB. In collaboration with WP5, a strategy of communication with the stakeholders will be implemented. The initial engagement will be achieved through a series of small stakeholder meetings to be organised under WP5, which will be followed up through a combination of contacts with specific stakeholders and involvement in the scientific workshops planned under task 3.3. The SRA will therefore be developed in an iterative manner that reflects both the scientific recommendations identified by the SAB and, wherever possible, the stakeholder priorities.

The MB will consider the final SAB report and stakeholder perspectives at M12, and will require a further 3
months to finesse and finalise the agenda before releasing the final SRA at M15. This will both establish the
framework for future activity under the JPIAMR as well as provide a reference point for any JPIAMR members
planning to develop their own national strategic approach in antimicrobial resistance. The SRA will be updated on a regular basis and the first update is planned at month 30.